Actively Recruiting
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
Led by University Health Network, Toronto · Updated on 2026-02-12
30
Participants Needed
1
Research Sites
230 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study will use Prostate Specific Membrane Antigen (PSMA) and (18)F-Fluorodeoxyglucose Positron Emission Tomography (FDG PET) imaging in patients with advanced prostate cancer to learn about tumor biology across disease stages and during treatment. This may help with treatment selection and potential response monitoring in the future.
CONDITIONS
Official Title
Dual PSMA and FDG PET Imaging for Patients With Advanced Prostate Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Male, age 65 18 years
- Histologically or cytologically confirmed prostate cancer (adenocarcinoma)
- Poor risk patients with metastatic castration-sensitive prostate cancer (mCSPC) at study enrollment
- De novo or recurrent high volume mCSPC as confirmed by conventional imaging (CT chest, abdomen, pelvis or MRI plus bone scan) before starting androgen deprivation therapy (ADT) and androgen receptor pathway inhibitor (ARPI)
- High or low volume mCSPC with PSA 64.0 after 6-8 months of starting ADT
- Willing to undergo study PET scans and remain under care of oncology or urology physician at Princess Margaret Cancer Center
- No PSMA or FDG PET imaging within 60 days before each specified study time point
- Patients in clinical trials eligible if meeting all other criteria
You will not qualify if you...
- Enrolled in randomized-controlled trials with unknown systemic therapy allocation
- Unable to undergo or complete PSMA and FDG PET imaging exams
- Unable to provide written consent personally or legally
- Conditions impairing ability to follow study procedures or attend follow-up as judged by physician
- Significant uncontrolled comorbidities affecting safety or imaging interpretation
- Having another active cancer
- On dialysis treatment
- Received other radioisotopes or investigational systemic agents within 5 half-lives before PET imaging
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Princess Margaret Cancer Centre
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
D
Di (Maria) Jiang, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here